Core Viewpoint - The strategic partnership between Daxing District and Jinma Pharmaceutical Group aims to enhance innovation and development in the pharmaceutical industry, particularly focusing on the approval and commercialization of the new drug, Amber Tetrahydroaminoacridine Tablets [1][3]. Group 1: Strategic Collaboration - Daxing District leaders met with Jinma Pharmaceutical Group to discuss the establishment of a headquarters and innovation center, new drug production, and commercialization efforts [3][9]. - The collaboration is expected to empower the capital's pharmaceutical and health industry, aligning with the district's goal of becoming a hub for life sciences [3][5]. Group 2: Regional Advantages - Daxing District is positioned as a core hub within the capital metropolitan area, benefiting from unique policy advantages due to its location in the airport economic zone, free trade zone, and comprehensive bonded zone [5][7]. - The district aims to develop three trillion-level industrial clusters, with a focus on life and health as a core engine for growth [5][7]. Group 3: Pharmaceutical Development - The "China Pharmaceutical Valley" is highlighted as the largest national-level biopharmaceutical park, featuring numerous high-tech enterprises and a complete service system from research to production [7][9]. - Jinma Pharmaceutical's focus on innovative drugs in the neurological field aligns with the district's strategic direction and development requirements [9][11]. Group 4: Future Plans - Jinma Pharmaceutical plans to establish a high-standard production and commercialization base for Amber Tetrahydroaminoacridine Tablets, leveraging the park's top-tier resources [14][15]. - The company aims to accelerate the development of innovative drugs for moderate to severe indications and acute ischemic stroke, utilizing the resources of six national clinical research centers [15][16]. Group 5: Commitment to Innovation - The partnership is seen as a commitment to building a future of pharmaceutical innovation, with both parties expressing strong confidence in the collaboration's potential [17][21]. - Jinma Pharmaceutical's strategic vision includes establishing a headquarters and innovation center in Beijing, aiming for a comprehensive transition to an innovative pharmaceutical company within 3-5 years [13][19].

Core Viewpoint - The article outlines the funding directions and application guidelines for the National Key Laboratory of Robotics and Intelligent Systems for the year 2025, emphasizing the laboratory's commitment to advancing robotics technology and its applications in various fields [1]. Funding Directions - The laboratory will provide funding in seven key areas for 2025, including: - Frontier key technologies in micro-nano robotics, such as targeted drug delivery and precise navigation [2]. - Research on humanoid robots and embodied intelligent systems, focusing on AI perception and autonomous decision-making [3]. - Intelligent medical robot systems, including multi-robot collaboration and brain-machine interface technologies [4]. - Key technologies for special robots, such as those used in extreme environments and autonomous decision systems [5]. - Intelligent autonomous robot systems for marine exploration, including ocean motion control and autonomous perception [6]. - Key technologies for aerospace manufacturing robots, focusing on environmental perception and autonomous navigation [7]. - Research on the cyber-physical security of industrial internet, addressing security threats and control mechanisms [8][9]. Application Conditions - Applicants must be researchers outside the Shenyang Institute of Automation, hold a PhD or above, and demonstrate the ability to lead research projects. Collaboration with fixed researchers from the laboratory is encouraged [10]. Funding Details - The funding amount for the open topics in 2025 ranges from 50,000 to 100,000 yuan, with a research period from September 1, 2025, to August 31, 2027 [11][12]. Results Management - Research outcomes must acknowledge the laboratory's support and include specific reporting requirements, such as publishing SCI papers and submitting a final report [13][15]. Funding Management - The funding will be managed according to national guidelines, primarily covering equipment, operational, and labor costs [14]. Application Process - Applications must be submitted by August 10, 2025, including a presentation and application form detailing the project's relevance and expected outcomes [16].